Intraocular Pressure and Its Response to Topical Corticosteroids in Diabetes

Becker, Bernard; Bresnick, George H.; Chevrette, Line; Kolker, Allan E.; Oaks, Merrill C.; Cibis, Andrea

doi:10.1001/archopht.1966.03850010479003

Cited by 110 publications

(99 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Preenchidos os critérios diagnósticos de hiperfunção da bolsa, tentou-se inicialmente normalizar a Po com tratamento clínico (atropina colírio a 1% uma gota de 12 em 12 horas e colírio de dexametasona a 0,1% ou similar, uma gota de 6 em 6 horas durante pelo menos trinta dias) (25) . Não tendo havido normalização da Po com o tratamento, os pacientes foram submetidos, sob consentimento informado, à ressecção da bolsa hiperfuncionante pelo mesmo cirurgião (SC).…”

Section: Relatos Dos Casosunclassified

“…As outras opções de tratamento: sutura de compressão (17) , avanço da conjuntiva com preservação da bolsa (25) , enxerto conjuntival (11)(12) , de fáscia lata (13) ou membrana amniótica (14) apresentaram resultados nem sempre satisfatórios como os aqui apresentados. A nosso ver, isto pode ser devido a fatores inerentes a cada técnica e, principalmente, à falha no diagnóstico correto da causa da hipotonia ocular.…”

Section: Comentáriosunclassified

“…Havendo vazamento de humor aquoso pela bolsa (teste de Seidel positivo), a nossa conduta não se restringe apenas à ressecção da bolsa mas também à colocação de um enxerto de esclera no local da bolsa para proteger a nova bolsa a ser formada e evitar a recidiva do vazamento. Na vigência de reação inflamatória intensa na câmara anterior, o tratamento deve ser feito com colírio cicloplégico (por exemplo, atropina a 1%, uma gota de oito em oito horas) associado ao uso de corticosteróide tópico (dexametasona ou betametasona a 0,1% ou prednisolona a 1%, uma gota de seis em seis horas) (25) e, às vezes, sistêmico. Se houver um DCC primário, a conduta cirúrgica (na falha do tratamento clínico convencional) é a drenagem do fluido supracoroidiano associada à injeção intracamerular de substân-cia viscoelástica e/ou a sutura do corpo ciliar.…”

Section: Comentáriosunclassified

See 2 more Smart Citations

Ressecção de bolsa hiperfuncionante para tratamento de hipotonia ocular crônica: relato de casos

Cronemberger

Santos

Oliveira

et al. 2004

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

Section: Relatos Dos Casosunclassified

Section: Comentáriosunclassified

See 1 more Smart Citation

Ressecção de bolsa hiperfuncionante para tratamento de hipotonia ocular crônica: relato de casos

Cronemberger

Santos

Oliveira

et al. 2004

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

“…All these factors might play a role in the increase in MYOC/TIGR expression in eyes with POAG. Topical treatment with dexamethasone can increase IOP (Armaly 1963a,b;Armaly 1965;Becker 1965), transforming growth factor-b is elevated in the aqueous humor of patients with POAG (Tripathi et al 1994), and an increase in IOP should cause increased mechanical tension and stretch in the trabecular meshwork. We hypothesize that the expression of MYOC/TIGR in the eye, and its increase in POAG is regulated at the level of transcription.…”

Section: Introductionmentioning

confidence: 99%

Regulation of human myocilin/TIGR gene transcription in trabecular meshwork cells and astrocytes: role of upstream stimulatory factor

et al. 2000

View full text Add to dashboard Cite

Background: Mutations in the myocilin (MYOC)/ TIGR gene are responsible for autosomal-dominant juvenile primary open-angle glaucoma (POAG). In patients with non-autosomal-dominant POAG, such mutations are rare, but the expression of MYOC/TIGR in the trabecular meshwork (TM) of the eye is considerably higher than in normals. We performed transfection, DNAse I footprinting, mutagenesis and electrophoretic mobility shift assays (EMSA) to identify elements responsible for the basal transcription of MYOC/TIGR in TM cells and astrocytes.

show abstract

“…Approximately 18-36% of the general population respond to steroid eye drops, with most often moderate elevations even after a short-term administration. [2][3][4][5] With steroid application on eyelid skin, increased IOP seems less common, but there are no controlled prospective studies available and several case studies attest to the fact that in long-term treatment, this risk should not be overlooked. [6][7][8] As a consequence, regular ophthalmologic examinations are recommended.…”

Section: Introductionmentioning

confidence: 99%

Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis

Nivenius

Ploeg

Jung³

et al. 2006

Eye

View full text Add to dashboard Cite

Aims The main objective of this explorative study was to evaluate if tacrolimus ointment could be safer than corticosteroid ointment, with special reference to the intraocular pressure in the treatment of eyelid eczema in patients with atopic keratoconjunctivitis (AKC). Secondary aims were to compare the effects of the treatments on eyelid eczema and their potential impact on ocular surface inflammation. Methods Tacrolimus 0.1% ointment and clobetasone butyrate 0.05% ointment were compared in a double-masked explorative crossover study. In total, 25 AKC patients were included. Each ointment was applied twice daily for 3 weeks, with 2 weeks of washout before, between, and after treatments. Efficacy was determined by eye examination and the patients' own symptom scoring. Cytology and cytokine measurements were performed on tear samples. Safety parameters were intraocular pressure, presence of bacteria and fungi, and the patients' reports of adverse events. The validity of the crossover design was explored with analysis of variance, and the effect of each medication was calculated with paired t-test and Wilcoxon paired test. Results A total of 20 patients completed the study. Both treatments were effective in reducing signs and symptoms of eyelid eczema, with a near superior benefit for tacrolimus in terms of eczema (total skin score) signs (P ¼ 0.05). No serious adverse events occurred and interestingly, intraocular pressure was not evidently affected by either treatment. Conclusion Tacrolimus 0.1% ointment is a promising alternative therapy for eyelid eczema in AKC patients. Long-term studies are needed to further determine the value of tacrolimus in this patient group.

show abstract

Intraocular Pressure and Its Response to Topical Corticosteroids in Diabetes

Cited by 110 publications

References 14 publications

Ressecção de bolsa hiperfuncionante para tratamento de hipotonia ocular crônica: relato de casos

Ressecção de bolsa hiperfuncionante para tratamento de hipotonia ocular crônica: relato de casos

Regulation of human myocilin/TIGR gene transcription in trabecular meshwork cells and astrocytes: role of upstream stimulatory factor

Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis

Contact Info

Product

Resources

About